The Broegelmann Research Laboratory (BRL) is lead by Professor Helena Erlandsson Harris, the Broegelmann chair of translation immunology and head of the Immunology and Rheumatology group. BRL is multinational research environment with group leaders originating throughout Europe and lab members throughout the world.
BRL is composed of five subgroups
Harris group - Translational studies on the immunopathogenesis of juvenile idiopathic arthritis (JIA) and the role of the alarmin HMGB1 in inflammation
Appel group - Stratification of patients with Sjögren’s disease, novel natural compounds to treat COVID-19 and cellular composition of intestines of IBS patients
Mydel group - The role of periodontitis in rheumaoid arthritis, cardiovascular disease and alzheimer's disease
Bryceson group - Molecular regulation of cytotoxic lymphocyte function in the context of inflammatory disease as well as cancer
Wahren-Herlenious group - Molecular basis for sex-bias in autoimmunity
Research performed spans from epidemiology, molecular, genetic and cellular studies to experimental models and studies on clinically well-characterized patient samples. Our ambition is to understand the molecular mechanisms active in different diseases and their subgroups, the underlying risk factors, and triggers. We believe research will pave the way to better, personalized treatment and ultimately to prevention of disease.
To facilitate this endeavour we collaborate closely with clinicians and scientists at Haukeland hospital, within Norway, across Scandinavia and worldwide. We additionally support the development and training of junior researchers in offering ECTS accredited courses and workshops through The Bergen Research School in Inflammation (BRSI).
The core financial support for BRL is generously provided by the Broegelmann Foundation, with the fund managed by the The Broegelmann Research Board.